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Abstract
Background The endothelial nitric oxide synthase (eNOS)
G894T gene polymorphism is associatedwith the risk of primary
hypertension (PH) and vascular complications in adults with PH.
Methods We explored the associations of the G894T poly-
morphism with 24-h ambulatory blood pressure, left ventric-
ular mass (LVM), carotid intima media thickness (cIMT), uri-
nary albumin excretion, oxidative stress and inflammatory
parameters in 126 children with newly diagnosed PH and in
83 healthy children.
Results Among the 126 children with PH 92 (73 %) had am-
bulatory hypertension and 34 (27 %) had severe ambulatory
hypertension. Left ventricular hypertrophy (LVH) was detect-
ed in 39 (31%) patients, cIMTof >2 standard deviation scores
in 21 (16.6 %) patients, albuminuria of >30 mg/24 h in 18
(14.3 %) patients and metabolic syndrome (MS) in 22
(17.5 %) patients. The frequency of the T allele was 52.4 %
in the PH group and 54.2 % in the control group (not signif-
icant), and in both groups the frequency of the T allele was
consistent with the Hardy–Weinberg equilibrium. Compared
with G allele carriers, hypertensive T allele carriers had in-
creased cIMT (p<0.05) and more severe albuminuria (not
significant, p=0.1); there was no difference between the
groups in hypertension severity and LVM. T and G allele
distribution did not differ between patients with and without
metabolic syndrome. No significant correlations between the
assessed parameters and the eNOS G894T gene polymor-
phism were found in the controls, although T allele carriers
tended to have an increased cIMT (p=0.09).
Conclusion The eNOS T allele is not more prevalent among
hypertensive children than among healthy ones, but it is asso-
ciated with early vascular damage in children with PH, inde-
pendent of metabolic abnormalities. No associations between
the eNOS G894T polymorphism and metabolic abnormalities
were found.
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Introduction
Subclinical target organ damage (TOD) in the form of left
ventricular hypertrophy (LVH) and/or increased carotid
intima-media thickness (cIMT) is already present in 30–
40 % of children with primary hypertension (PH) at the diag-
nosis of elevated blood pressure (BP) [1–5]. Several complex
mechanisms have been hypothesized to play a key role in the
development of vascular complications, including metabolic
and inflammatory processes, as well specific genetic predis-
position. Some data indicate the involvement of endothelial
nitric oxide synthase (eNOS) in the development of PH and
the association of a relative or absolute decrease of eNOS
activity with various vascular complications in response to
hemodynamic workload [6]. Other data indicate that relative
or absolute defects in the production of nitric oxide (NO) by
eNOS or an abundant degradation of NO by enhanced oxida-
tive stress (reactive oxygen species) is associated with various
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vascular complications in response to hemodynamic workload
[6, 7]. In addition, impaired NO bioavailability can also be
related to a cellular defect in skeletal muscle tissue, where NO
regulates many metabolic and contractile processes, such as
basal glucose transport [8].
Several polymorphisms of the eNOS gene have been identi-
fied, including a single nucleotide polymorphism (SNP) in the
promoter region (T−789C), a variable tandem repeat in intron 4
and a Glu298Asp SNP in intron 7. A glutamic acid to aspartic
acid substitution at amino acid position 298 is caused byGuanine
(G) to thymine (T) transversion at nucleotide 894 of exon 7 [9].
The eNOS 894 T variant has lower activity and has been found to
associate with coronary heart disease, carotid atherosclerosis and
endothelial dysfunction [10–17]. This variant is also associated
with enhanced vasoconstrictive response to phenylephrine, hy-
pertensive response to endurance training and development of
hypertension [13, 18, 19]. However, it seems that both distribu-
tion and clinical relevance of the eNOS G894T polymorphism
vary among different ethnic groups [20, 21].
To date, the relationship between the eNOS G894T gene
polymorphism and vascular complications in hypertensive
children has not been investigated. The main intermediate
phenotype of children with PH includes metabolic abnormal-
ities typical of metabolic syndrome, oxidative stress and im-
mune activation. These abnormalities are strictly associated
with TOD [22–25]. Although there are a few pediatric studies
analyzing associations between eNOS polymorphisms and hy-
pertension, obesity and metabolic syndrome, we are not aware
of any pediatric study analyzing the associations of eNOS
polymorphisms with hypertensive TOD in children with PH
[26–28]. Thus, the aim of our study was to explore associa-
tions of the eNOS G894T gene polymorphism with TOD
markers, oxidative stress and metabolic and inflammatory pa-
rameters in an ethnically homogenous group of 126 children
with newly diagnosed PH and in 83 healthy children.
Patients and methods
Patients
White, Caucasian children and adolescents admitted consec-
utively to the The Children’s Memorial Health Institute during
the period 2005–2008 for investigation of suspected arterial
hypertension who had not been previously treated with anti-
hypertensive drugs and in whomPHwas ultimately diagnosed
were eligible for entry into the study. Of these 200 children,
126 (median age 15 years, age range 5–18 years; 31 girls, 95
boys) with untreated PH who completed all investigative pro-
cedures were recruited to the study. PH was diagnosed after a
thorough clinical and laboratory diagnostic work-up accord-
ing to recently published recommendations [29]. In all pa-
tients the diagnosis was confirmed by 24-h ambulatory blood
pressure measurement (ABPM). Recordings lasting at least
20 h with at least 80 % of records available for analysis were
considered to be valid. BP values were calculated from the
ABPM as the mean 24-h systolic BP (SBP/24 h) and diastolic
BP (DBP/24 h) and presented as absolute values and as the
SBP and DBP indices (SBPi and DBPi, respectively)
calculated as the ratio of SBP or DBP to the 95th percentile
for age and gender based on the pediatric ABPM reference data
[30]. The recently published classification system based on
ABPM was used to classify patients as having normal blood
pressure, ambulatory hypertension and severe ambulatory
hypertension [31]. The exclusion criteria were: diagnosis of
secondary hypertension, previous use of antihypertensive
drugs, presence of any significant chronic disease (except for
PH) and acute disease, including infections, in the 6 weeks
immediately preceding enrollment. Patients with incomplete
biochemical data were also excluded.
Controls
The control group consisted of 83 Caucasian healthy, normo-
tensive children with a median age 12 (range 5–18) years (43
girls, 40 boys), recruited voluntarily from schools. None of
these children had any significant chronic or acute disease,
including infections, within the 6 weeks immediately preced-
ing enrollment.
Molecular studies
EDTA-anticoagulated venous blood samples were collected
from all participating children. DNAwas extracted from blood
leukocytes using the phenol method. Polymorphism of eNOS
G894T gene was evaluated by restriction fragment length
polymorphism (RFLP) PCR.
Anthropometrics and biochemical assays
All patients and controls underwent the following assess-
ments, unless indicated otherwise, which included
anthropometrical measurements, such as body mass index
(BMI), waist circumference (WC) (patients only) and waist-
to-hip ratio (WHR) (patients only). Obesity and overweight
was diagnosed according to the International Obesity Task
Force (IOTF) recommendations [32]. In all patients and con-
trols, serum glucose and insulin, blood lipids, serum homo-
cysteine, serum uric acid and C-reactive protein [high-
sensivity C-reactive protein (hsCRP)], serum asymmetric
dimethyloarginine (ADMA) levels, oxidative stress [thiobar-
bituric acid reactive substances (TBARS) and oxidized low-
density lipoprotein cholesterol (oxyLDL) concentration] and
anti-oxidative defense [reduced glutathione (GSH) concentra-
tion and glutathione peroxidase (GPx) activity] were mea-
sured. Because some of our patients were under 10 years of
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age, metabolic syndrome (MS) was diagnosed when at least
three criteria were fulfilled [BMI ≥95th percentile for age and
gender; arterial hypertension; serum triglycerides >110 mg/dl;
fasting plasma glucose >100 mg/dl or >140 mg/dl at 2 h of
oral glucose tolerance test; high-density lipoprotein (HDL)
cholesterol <40 mg/dl] [22].
cIMT measurements
The cIMTwas measured both in controls and PH patients by
ultrasound according to methodology described previously
[3]. The median and standard deviation (SD) of normal values
for cIMT were obtained from normative data published else-
where [33].
Echocardiography
Echocardiography (ECHO) was performed in all patients, but
due to organizational problems ECHO was not performed in
controls. All ECHO examinations were performed by one
examiner blinded to the severity of PH and effectiveness of
treatment. ECHOmeasurements were performed according to
the American Society of Echocardiography guidelines and to
standardize the left ventricular mass to height ratio, the left
ventricular mass index (LVMi) was calculated according to
the de Simone formula [34]. LVH was defined as an LVMi
value of >95th percentile for age and gender, based on the
pediatric LVMi reference data [35].
Laboratory investigations
Blood samples were taken after 12 h of fasting and immedi-
ately sent to the laboratory. Plasma glucose level was mea-
sured by a Siemens Dimension chemistry analyzer (Siemens
Medical Solutions, Malvern, PA) . Plasma insulin concentra-
tions and glycated hemoglobin (HbA1c) were measured by
radioimmunoassay. An oral glucose tolerance test was carried
out in all patients after oral ingestion of 1 g/kg body weight
(maximum 75 g) of glucose. Insulin resistance, as described
previously, was expressed as homeostasis model assessment
for insulin resistance (HOMA-IR) and as the total
triglycerydes:HDL-cholesterol (TTG/HDL) ratio.
The CRP concentration (hsCRP) was determined using
highly sensitive immunoturbidimetry (Orion Diagnostica, Es-
poo, Finland). Lipids and uric acid (UA) concentrations were
determined with standard laboratory procedures. Plasma lipid
peroxides were determined with the spectrofluorometric
method of Yagi and expressed as TBARS. GSH concentration
and GPX activity were used as indicators of antioxidant
status and were measured spectrophotometrically in
erythrocytes (Oxis Bioxytech GSH-420 and GPx-340
assays, respectively; Oxis International Inc., Foster City,
CA). OxyLDL and ADMA concentrations were
measured by enzyme-linked immunosorbent assay
(ELISA) using a commercially available kit. Urinary albumin
excretion in 24-h samples was determined by the
immunonephelometric method.
The laboratory procedures have been described in detail in
a previous study [23].
Statistics
Because the analyzed groups included subjects of different
age and gender, BMI, WC and cIMT values were expressed
both as absolute values and as standard deviation scores
(SDS) for age and gender. LVM values (in grams) were stan-
dardized to height in meters2.7. Homogeneity of variance was
checked with the Levene test. Continuous variables with a
normal distribution were compared by the Student t test for
independent variables and expressed as the mean and SD.
Continuous values with a non-normal distribution were com-
pared by the Mann–Whitney U test and expressed as the me-
dian and range. Comparison between groupswas evaluated by
the analysis of variance (ANOVA) test with Bonferroni cor-
rection. Dichotomous variables were compared using the Chi-
square test. Molecular predictors of TOD were assessed in a
stepwise regression analysis. The dependent variables were
absolute, and standardized values of cIMT and variables
which correlated with TOD or differentiated patients with or
without TOD were chosen as independent variables. Statisti-
cal analysis was done using SPSS12.0PL software (IBM
Corp., Armonk, NY).
Calculations to determine whether observed genotype fre-
quencies were consistent with the Hardy–Weinberg equilibri-
um, which means that in a population in the absence of
disturbing factors they will remain constant from one genera-
tion to the next, were performed with the Court online calcu-
lator (http://www.tufts.edu/~mcourt01/Documents/Court%
20lab%20-%20HW%20calculator.xls). P values of <0.05
were regarded as statistically significant, and those ranging
between 0.05 and 0.1 were regarded as a statistical tendency.
Results
Clinical and biochemical phenotype
Children with PH had significantly greater BMI, higher serum
UA, hsCRP, homocysteine, lipoprotein a, TTG/HDL ratio,
plasma insulin, HOMA-IR, ADMA and oxyLDL and lower
GPx activity and GSH concentration than normotensive chil-
dren. They also had significantly greater cIMT values than
healthy children. Children with PH had higher triglyceride
concentrations and a lower birth weight than normotensive
children, but the difference was non-significant for both pa-
rameters (Tables 1, 2).
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In the PH group, 92 (73 %) children had ambulatory hy-
pertension and 34 (27 %) children had severe ambulatory
hypertension. MS was diagnosed in 22 (17.5 %) pa-
tients and in none of the controls. Also in this patient
group, 39 (31 %) children had LVH, 21 (16.6 %) chil-
dren had cIMT of >2 SDS and 18 (14.3 %) children
had albuminuria of >30 mg/24 h.
We found a significant correlation between the LVMi and
all of the assessed anthropometrical parameters [BMI (r=
0.34), BMI-SDS (r=0.38), WC (r=0.39), WC-SDS (r=
0.34) and WHR (r=0.37)]. The cIMT-SDS correlated with
SBP/24 h (r=0.19, p<0.05), hsCRP (r=0.25, p<0.05),
GPx (r=0.23, p<0.05) and albuminuria (R=0.21,
p<0.05). Positive correlations were found between the
Table 1 Demographic, clinical and genetic data in patients with primary hypertension and control group
Variable Control group, N=83 (n = 40 boys) PH patient group, N=126 (n = 95 boys) p
Age (years) 12 (5–18) 15 (5–18) ns
Birth weight (g) 3520 (1960–4400) 3355 (1410–5250) 0.06
BMI (kg/m2) 19.2±3.9 24.8±4.5 <0.001
BMI SDS 0.27±1.13 1.75±1.7 <0.001
WC (cm) n.a. 84 (53–111) -
WC SDS n.a. 1.62 (−2.03 to 6.12) -
cIMT (mm) 0.40 (0.31–0.53) 0.43 (0.34–0.63) <0.001
cIMT SDS 0.50 (−2.27 to 3.46) 0.97 (−1.37 to 7.83) <0.001
LVMi (g/m2.7) n.a 35.3 (19.1–62.3) -
Number of patients with GT and TT alleles 45 (54.2 %) 66 (52.4 %) ns
Number of patients with TT alleles 8 (9.6 %) 13 ( 10.3 %) ns
Data are presented as the mean ± standard deviation (SD), as the median with the range in parenthesis or as a number with the percentage in parenthesis,
as appropriate
PH Primary hypertension, BMI body mass index, cIMT carotid intima-media thickness, LVMi left ventricular mass index, SDS standard deviation score,
n.a. not assessed, GT carriers of G894 and T894 allele, TT T894 homozygotes, WC waist circumference
Table 2 Laboratory data for patients with primary hypertension and the control group
Variable Contro group (N=83) PH patient group (N=126) p
Cholesterol (mg/dl) 175.6±39.1 173.6±33.7 ns
Triglicerydes (mg/dl) 69 (38–312) 84 (28–425) 0.05
HDL-cholesterol (mg/dl) 46.6±9.8 44.6±9.6 ns
TTG/HDL 1.48 (0.64-15) 1.84 (0.58–42) 0.01
LDL-cholesterol (mg/dl) 111 (60–185) 110 (43–226) ns
Lp(a) (mg/dl) 11.7±7.6 15.5±11.7 0.02
Uric acid (mg/l) 4.08±0.63 5.48±1.19 <0.001
Homocysteine (μmol/l) 8.9±3.4 10.2±3.5 0.02
hsCRP (mg/dl) 0.44 (0.12–6.74) 0.74 (0.02–4.68) 0.01
Fasting glucose (mg/dl) 90 (78–105) 85 (67–109) 0.001
Fasting insulin (mU/ml) 9 (3.3–15) 12.8 (3–39) 0.001
HOMA-IR 1.9 (0.74–3.28) 2.78 (1.11–8.77) 0.001
GPx (U/gHb) 32.8 (20.1–42.1) 31.5 (23.8–39.9) 0.005
GSH (μmol/l) 792.5 (253.2–889.1) 760.1 (441.7–889.4) 0.001
ADMA (μmol/l) 0.46 (0.15–1.30) 0.55 (0.25–1.45) 0.02
oxyLDL (mU/ml) 260.9 (0.21–1272) 400.15 (45.8–1372) 0.008
Albuminuria(mg/24 h) n.a. 14.7 (2–270)
Data are presented as the mean ± SD or as the median with the range in parenthesis, as appropriate
HDL high-density lipoprotein-cholesterol, TTG total triglycerydes, LDL low-density lipoprotein-cholesterol, Lp(a) lipoprotiein a, hsCRP high-sensivity
C-reactive protein,HOMA-IR homeostasis model assessment for insulin resistance,GPx glutathione peroxidase,GSH reduced glutathione,ADMA serum
asymmetric dimethyloarginine, oxyLDL oxidized LDL-cholesterol, ns not significant
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LVMi and values of albuminuria and hsCRP (R=0.22,
p<0.05) and a negative correlation was found with birth
weight (R=−0.27, p<0.05).
Compared to hypertensive children with a cIMT of <2
SDS, hypertensive children with cIMT of >2 SDS presented
significantly higher values of SBP/24 h (134±9 vs. 128±
8 mmHg; p<0.05), SBPi/24 h (1.05±0.07 vs. 1.01±0.06;
p<0.05) and albuminuria [24.2 (4.7–270) vs. 13.3 [2–172]
mg/24 h; p<0.05].
In the control group, cIMT-SDS trended to correlate with
hsCRP (R=0.21, p=0.06) and fasting glucose (R=0.24, p=
0.07). No significant differences between controls with a
cIMT of>2 SDS (12 patients, 14.5 %) and those with a cIMT
of <2 SDS (71 patients , 85.5 %) were found.
Molecular studies—baseline comparisons
The frequency of the T allele was 52.4 % in the PH group and
54.2 % in the control group [not significant (n.s.)], and in both
groups observed genotype frequencies were consistent with
the Hardy–Weinberg equilibrium ( PH: chi2=0.06, p=0.798,
controls: chi2=0.054, p=0.8159).
Hypertensive Tallele carriers had greater cIMT, cIMT-SDS
(both significant at p<0.05) and albuminuria (n.s. at p=0.1)
than G allele carriers but did not differ in relation to hyperten-
sion severity and LVMi (Table 3). No significant correlations
between the assessed parameters of oxidative stress and
anti-oxidative defense and eNOS G894T gene polymor-
phism were found. T and G allele distribution did not
differ between patients with and without MS [TT fre-
quency: 3 (13.6 %) patients vs. 10 (9.6 %) patients, respec-
tively; GG: 10 (45.5 %) patients vs. 50 (48.1 %) patients,
respectively; not significant].
In comparison to GG homozygotes, TT homozygotes with
PH had higher cIMT [0.465 (0.36–0.57) vs. 0.43 (0.34-0.52)
mm; p=0.02], cIMT-SDS [1.49 (−0.35 to 2.7) vs. 0.86 (−1.05
to 3.12); p=0.03] and a tendency to higher relative wall thick-
ness (RWT) [0.36 (0.28–0.45) vs. 0.32 (0.23–0.59) mm; p=
0.1]. GG homozygotes had a significantly lower birth weight,
higher visceral fat accumulations, higher hsCRP and higher
heart rate in ABPM than the other groups (Table 3).
In the control group no significant correlations between
assessed parameters and the eNOS G894T gene polymor-
phism were found. However, T allele carriers tended to have
greater cIMT than GG homozygotes [0.41(0.33-0.53) mm vs.
0.40 (0.31 -0.48) mm; p=0.09).
TT homozygotes with PH in comparison to TT homozy-
gotes in the control group presented only significantly higher
values of cIMT (p=0.04) and a tendency to higher cIMT SDS
(p=0.07) (Table 4).
Stepwise regression analysis revealed that the main predic-
tors of increased cIMT-SDS (R2=0.23, F=1.8) were the
G894T gene polymorphism (beta=0.342, p=0.01) and GPx
activity (beta=0.288, p=0.047). For absolute cIMT values
(R2=0.22, F=1.97) the main predictors were also G894T gene
polymorphism (beta=0.343, p=0.01) and GPx activity (beta=
0.28, p=0.049).
Discussion
The main finding of our study is that the T894 allele of the
eNOS gene is associated with early vascular damage in chil-
dren with PH independently of metabolic abnormalities. This
association was not found in normotensive children.
Reports showing an association between the G894T poly-
morphism, vascular complications and hypertension in
humans are not consistent [10–17, 36]. The meta-analysis of
Niu and Qi indicated that the T894 allele may be associated
with an increased risk of hypertension. However, this associ-
ation exhibited no significance in white people, suggesting the
heterogeneous associations of G894T polymorphism in spe-
cific populations (Asian populations) [21]. Similarly, inter-
ethnic differences in the distribution of eNOS genetic variants
have been described in various studies, including comparisons
of black and white Brazilians and of Caucasians, Afro-
Americans and Asians [20, 37]. Thus, our findings may be
limited only to a population of Caucasian children.
In our homogenous group of Caucasian children the fre-
quency of the T allele was 52.4 % in the PH group and 54.2 %
in the control group; this slight difference between the groups
was not significant. Also, we did not find any differences in
BP levels or prevalence of MS between the analyzed geno-
types. These results are similar to those of Miranda at al. who
did not find any association between the G894T polymor-
phism and MS in obese children and adolescents [28]. How-
ever, these authors indicated that the CC genotype for the
T786C polymorphism of eNOS is associated with MS [28].
In our study, hypertensive T allele carriers had greater
cIMT and tended to have greater albuminuria that the G allele
carriers (Table 3). Moreover, in comparison to the GG homo-
zygotes, the TT homozygotes presented with higher birth
weight, lower visceral fat accumulation, lower hsCRP and
lower heart rate in ABPM, a significantly higher cIMT and a
tendency to greater RWT. Similarly, in the control group, T
allele carriers tended to have greater cIMT. The correlation
between T allele frequency and intima-media thickening has
also been found in some groups of adult patients [14–16].
Some authors have reported that the 894 T allele of the eNOS
polymorphism is also associated with carotid atheroma and
with the presence, extent and severity of angiographically
assessed coronary artery disease [12, 13]. Czarnecka et al.
found higher cIMT values in both hypertensive T allele car-
riers and among T allele carrier offspring of hypertensive pa-
tients [15]. Our finding of an association between the 894 T
allele and greater cIMTonly in hypertensive children suggests
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that genetic polymorphism of the eNOS gene predisposes to
arterial injury only when the arterial wall is exposed to higher
blood pressure. However, it does not mean that the eNOS gene
polymorphism is associated with elevated blood pressure.
Arterial remodeling in HT patients is mainly determined by
reduced NO bioavailability. Apart from the significance of the
genetically conditioned decreased eNOS release/availability,
obesity and inflammation also lead to reduced eNOS bioavail-
ability and consequently to cardiovascular diseases [26, 38,
39].
Jiménez-Morales found that their subjects with the TT ge-
notype displayed a lower vascular response (lower increase in
post-ischemic capillary flow) compared with TG and GG ge-
notypes and that this response was improved after an intake of
meals rich in high-phenol virgin olive oil [40]. Similarly,
Leeson et al. found a positive relationship between n-3 fatty
acid level and flow-mediated dilation in 894 Tcarriers, but not
in G894 homozygotes. Additionally, among men, smoking
has been associated with lower flow-mediated dilation in T
allele carriers but not in GG homozygotes [17]. A study of the
Table 3 Demographic, clinical and laboratory data in patients with primary hypertension according to eNOS G894T genotype variants
Variables GG (1) GT+TT (2) GT (2a) TT (2b) p
N 60 66 53 13
Birth weight (g) 3325 (1790–4200 ) 3400 (1410–5250) 3300 ( 1410–4000) 3500 (3140–5250) 1 vs. 2b p=0.03
2a vs. 2b p=0.06
BMI 24.9±4.4 24.8±4.6 24.6±4.2 25.6±6.3 ns
BMI-SDS 1.55 (−1.26 to 6.03) 1.64 (−0.81 to 9.69) 1.64 (−1.56 to 9.69) 1.79 (−0.81 to 5.8) ns
WC (cm) 85.14±10.8 81.23±12.9 81.23±12.08 81.33±16.6 ns
WC-SDS 1.82 (−0.94 to 4.88) 1.38(−2.03–6.1) 1.35(−2.03–6.12) 1.40 (−1.1 to 4.5) ns
WHR 0.86±0.07 0.83±0.06 0.82±0.07 0.84±0.07 1 vs. 2 p=0.01
1 vs. 2a p<0.01
SPBP/24 h (mmHg) 129±8 130±8 130±8 130±9 ns
SBPi/24 h 1.02 (0.89–1.17) 1.02(0.91–1.23) 1.02 (0.92–1.20) 1.03 (0.90–1.23) ns
DBP/24 h (mmHg) 73±6 72±8 72±7 73±9 ns
DBPi/24 h 0.95 (0.81–1.23) 0.94 (0.69–1.27) 0.94 (0.82–1.27) 0.94 (0.8–1.12) ns
HR/24 h (/min) 82±10 77±12 77±12 78±10 1 vs. 2 p=0.02
1 vs. 2a p=0.03
1 vs. 2b p=0.1
IMT (mm) 0,43 (0.34–0.52) 0.44 (0.345–0.62) 0.43 (0.345–0.62) 0.465 (0.36–0.57) 1 vs. 2 p=0.01
1 vs. 2a p=0.05
1 vs. 2b p=0.02
IMT-SDS 0,86 (−1.05 to 3.12) 1.03 (−1.37 to 7.2) 1 (−1.37–7.2) 1.49 (−0.35 to 2.7) 1 vs. 2 p=0.03
1 v.s 2a p=0.06
1 vs 2b p=0.03
Albuminuria (mg/24 h) 13.5 (2–57.6) 15.2 (4.6–250) 14.7 (4.6–250) 16.2 (9.3–54.6) 1 vs. 2 p=0.17
LVMi (g/m2.7) 35.2±8.0 36.9±9.4 36.6±9.4 37.7±9.6 ns
RWT (mm) 0.32 (0.23–0.59) 0.36 (0.23–0.59) 0.35 (0.23–0.59) 0.36 (0.28–0.45) 1 vs. 2b p=0.1
TTG/HDL 1.87 (0.78–-12.9) 1.84 (0.58–42.5) 1.9 (0.58–42.5) 1.77 (0.78–2.91) ns
hsCRP (mg/l) 0.76 (0.02–3.98) 0.69 (0.05–4.68) 0.84 (0.05–4.68) 0.41 (0.14–0.82) 1 vs. 2b p=0.05
2a vs. 2b p=0.06
Fasting insulin (mU/ml) 12.9 (6.4–39) 12.8 (3–36) 12.8 (3–36) 12.9 (6.7–30) ns
HOMA -R 2.86 (1.26–8.77) 2.68 (1.1–7.9) 2.73 (1.1–7.92) 2.64 (1.38–6.23) ns
HbA1c (%) 5.4 (4.1–6.8) 5.3 (4.2–6.6) 5.3 (4.2–6.6) 5.0 (4.5-5–6) 1 vs. 2 p=0.11
1 vs. 2b p=0.1
GPx (U/gHb) 31.6 (28.3–39.9) 31.4 (23–8-38.1) 31.3 (23.8–38.1) 33.2 (30.8–36.9) 2a vs. 2b p=0.07
Number of patients with MS 10 12 9 3 ns
Data are presented as the mean ± SD, as the median with the range in parenthesis or as a number, as appropriate
GGG894 homozygotes,GTcarriers of G894 and T894 allele, TT T894 homozygotes,WHRwaist-to-hip ratio, SBP/24 hmean systolic blood pressure in
24-h ambulatory blood pressure monitoring (ABPM), SBPi/24 h index of SBP/24 h, DBP/24 h mean diastolic systolic blood pressure in 24-h ABPM,
DBPi/24 h index of DBP/24 h, HR/24 h mean heart rate in 24-h ABPM, RWT relative wall thickness, HbA1c glycated hemoglobin, MS metabolic
syndrome
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functional consequences of the Glu298Asp polymorphism of
the eNOS gene in healthy volunteers found that TT allele
carriers, i.e. Asp homozygotes, had decreased vasodilatory
response to acetylcholine in the forearm, which indicates
blunted endothelial-dependent vasodilation [41]. The role of
the Glu298Asp polymorphism in the regulation of blood pres-
sure status was recently evaluated in over 2000 children and
adolescents participating in the European Youth Heart Study.
Asp homozygotes were found to have slightly higher blood
pressure values at rest compared to Glu298 carriers. Interest-
ingly, this difference was found only in adolescents (pubertal
and post-pubertal subjects), but not in prepubertal children.
Moreover, physical activity modified the genetic effect, which
was most apparent in inactive subjects [27].
It is suspected that the Glu298Asp polymorphism reduces
the degree of interaction of eNOS with caveolin-1 and thereby
hinders the localization of eNOS in caveolae and diminishes
shear-dependent eNOS activation [16, 42]. However, the mo-
lecular mechanism of the effects of different eNOS polymor-
phisms is not clear. In studies not limited to the analysis of
SNPs but which analyzed the effects of different haplotypes of
eNOS, such as a SNP in the promoter region (T−789C), a var-
iable tandem repeat in intron 4 and a Glu298Asp SNP in
intron 7, subjects who had haplotype BC-4b-Glu^ had the
lowest plasma and whole blood nitrite levels [43, 44].
Interestingly, there marked inter-ethnic differences in the
distribution of different haplotypes have been observed
[37]. Souza-Costa at al. compared the distribution of
some eNOS haplotypes in normotensive obese/hypertensive
obese children with healthy controls and found that only the
CbG haplotype constellation was more frequent in hyperten-
sive obese children in comparison to the other analyzed
group [26].
Following these observations, the eNOS modulatory role
of statins and virgin olive oil may have an influence on
functional regulation of the cardiovascular system and may
offer new perspectives for the better use of statins and
phenol-rich olive oil in ameliorating cardiovascular dis-
orders, especially in patients with downregulated eNOS
function, such as carriers of the TT allele of the G894T
polymorphism. Moreover, the interaction between the
genetic variation in eNOS and BP may also be modified
by physical activity. Physical activity may strengthen
the production and effect of NO in the regulation of BP
through endothelial vasodilatation and could be an effective
way of controlling BP in individuals with a genetic predispo-
sition toward hypertension or hypertensive children with sub-
clinical arterial injury [27, 45].
The main limitation of our study was the low number of
patients and controls. Because of this, some differences be-
tween groups were not statistically significant. It is important
to emphasize that some authors have failed to find any rela-
tionship between the 894 T variant and the risk of atheroscle-
rosis [18, 46]. In the systematic assessment and meta-analyses
of candidate gene polymorphisms studied in more than 5000
subjects, including the most extensively studied polymor-
phisms for cIMT, the apolipoprotein E ε2/ε3/ε4 polymor-
phism is the only one to date for which a convincing associ-
ation with cIMT has been demonstrated [47]. Even if the
number of patients included in our study is small, it should
be emphasized that all participants were clinically well-
defined and selected. Our study is the first to show an associ-
ation between the eNOS G894T polymorphism and early vas-
cular damage in children with untreated PH. Certainly, we
have examined only one selected polymorphism, which pro-
vides less verified information. PH is a complex state that
involves many genes apart from the eNOS gene and is not
entirely explained by genetic factors. Other risk factors may
modify the effects of eNOS polymorphisms on the risk of
vascular damage.
Table 4 Comparison of some
clinical and laboratory data of TT
allele carriers in the control and
primary hypertension group
Variables TT controls TT patients with PH p
Number of pts (%) 8 (9.6 %) 13 (10.3 %) ns
BMI (kg/m2) 20.7±3.7 25.6±6.3 0.07
BMI-SD 0.62±0.98 1.89±2.05 ns
cIMT (mm) 0.41 (0.31–0.44) 0.46 (0.37–0.57) 0.04
cIMT-SDS 0.67 (−1.58 to 1.72) 1.49 (−0.35 to 2.52) 0.07
hsCRP (mg/l) 0.24 (0.15–0.71) 0.41 (0.14–0.82) ns
TTG/HDL 1.8 (1.0–2.9) 1.8 (0.8–2.9) ns
Fasting insulin (mU/ml) 12 (7.6–12) 12.9 (6.7–30) 0.1
HOMA-IR 2.42 (1.06–2.85) 2.64 (1.38–6.23) ns
Data are presented as the mean ± SD, as the median with the range in parenthesis or as a number with the
percentage in parenthesis, as appropriate
BMI body mass index, cIMT carotid intima-media thickness, hsCRP high-sensivity C-reactive protein, TTG/
HDL total triglycerydes/ high density lipoprotein cholesterol, HOMA-IR homeostasis model assessment for
insulin resistance
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In conclusion, we demonstrate for the first time in children
with PH that the G894T polymorphism of the eNOS gene is
associated with early vascular damage independent of meta-
bolic abnormalities.
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